NCT03720860 Inflammatory Mediators of Acute Kidney Injury in Intensive Care
| NCT ID | NCT03720860 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uppsala University |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2018-01-01 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute kidney injury (AKI) affects more than 50% of patients admitted to the intensive care unit. The most common underlying cause is sepsis. Severe AKI in combination with sepsis is associated with high mortality. The mechanisms for sepsis-induced AKI are largely unknown. Our hypothesis is that the inflammatory response to an infection cause collateral damage to host tissue and contributes to the development of AKI. In this study we want to investigate the presence of novel inflammatory mediators in patients with sepsis, patients subjected to major surgery (sterile inflammation) and non-inflamed patients and correlate their levels with the risk for AKI.
Eligibility Criteria
Inclusion Criteria: Patients admitted to the intensive/post operative care unit * with septic shock or * post major surgery or * after intoxication with a chemical compund Exclusion Criteria: * Pregnancy or * Breast feeding or * Chronic kidney disease or * intoxication with nephrotoxic compund or * lack of informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03720860 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03720860 currently recruiting?
Yes, NCT03720860 is actively recruiting participants. Contact the research team at sara.bulow.anderberg@akademiska.se for enrollment information.
Where is the NCT03720860 trial being conducted?
This trial is being conducted at Uppsala, Sweden.
Who is sponsoring the NCT03720860 clinical trial?
NCT03720860 is sponsored by Uppsala University. The trial plans to enroll 100 participants.